

**Supplemental Table 1.**

Clinicopathologic characteristics of patients with lung adenocarcinomas from the three institutions\*

<b>Characteristic</b>	<b>BWH</b>	<b>UP</b>	<b>MGH</b>	<b>P value</b>	<b>Total</b>
<b>Number of cases</b>	116	111	131		358
<b>Sex - n(%)</b>				<b>0.5</b>	
Male	43 (37)	48 (43)	47 (36)		138 (39)
Female	73 (63)	63 (57)	84 (64)		220 (61)
<b>Age (years)</b>				<b>0.002</b>	
Median	67	70	63		66
Range	34-87	41-88	29-90		29-90
<b>Smoking Status - n (%)</b>				<b>&lt;0.0001</b>	
Never smoker	14 (12)	19 (17)	52 (40)		85 (24)
Smoker	84 (72)	80 (72)	79 (60)		243 (68)
Unkown	18 (16)	12 (11)	0 (0)		30 (8)
<b>Tumor Size (cm)**</b>				<b>0.0003</b>	
Median	2.3	2.2	3		2.5
Range	0.6-12	0.6-7.5	0.3-11		0.3-12
<b>Tumor Status† - n (%)</b>				<b>0.72</b>	
pT1	41 (35)	45 (41)	21 (16)		107 (30)
pT2	52 (45)	51 (46)	18 (14)		121 (34)
pT3	6 (5)	3 (3)	1 (1)		10 (3)
pT4	17 (15)	12 (11)	8 (6)		37 (10)
Unknown	0 (0)	0 (0)	83 (63)		83 (23)
<b>Lymph Node Status† - n(%)</b>				<b>0.007</b>	
Negative	68 (59)	82 (74)	30 (23)		180 (50)
Positive	34 (29)	25 (23)	28 (21)		87 (24)
Unkown	14 (12)	4 (4)	73 (56)		91 (25)
<b>Stage† - n (%)</b>				<b>&lt;0.0001</b>	
I	63 (54)	78 (70)	28 (21)		169 (47)
II	15 (13)	12 (11)	2 (2)		29 (8)
III	29 (25)	21 (19)	17 (13)		67 (19)
IV	9 (8)	0 (0)	84 (64)		93 (26)

\*P value is based on the comparison between MGH patients and all other patients. Due to rounding not all percentages total 100

\*\*Based on 83 samples.

†Tumor and node status were based on pathology evaluation (pStage). Stage was based on both radiology and pathology evaluation (cStage).